

REGISTERED NUMBER: 11079986 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD
23 NOVEMBER 2017 TO 31 DECEMBER 2018
FOR
GM BIOPHARMA LTD

GM BIOPHARMA LTD (REGISTERED NUMBER: 11079986)

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 23 NOVEMBER 2017 TO 31 DECEMBER 2018**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

GM BIOPHARMA LTD

COMPANY INFORMATION

FOR THE PERIOD 23 NOVEMBER 2017 TO 31 DECEMBER 2018

DIRECTOR:

Mr A Uddin

REGISTERED OFFICE:

30-31
Furnival Street
London
EC4A 1JQ

REGISTERED NUMBER:

11079986 (England and Wales)

GM BIOPHARMA LTD (REGISTERED NUMBER: 11079986)

BALANCE SHEET 31 DECEMBER 2018

	Notes	£
CURRENT ASSETS		
Debtors	4	9,243
Cash at bank and in hand		1,812
		11,055
CREDITORS		
Amounts falling due within one year	5	10,955
NET CURRENT ASSETS		100
TOTAL ASSETS LESS CURRENT LIABILITIES		100
CAPITAL AND RESERVES		
Called up share capital	6	100
SHAREHOLDERS' FUNDS		100

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2018.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2018 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 20 August 2019 and were signed by:

Mr A Uddin - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 23 NOVEMBER 2017 TO 31 DECEMBER 2018**

1. STATUTORY INFORMATION

GM Biopharma Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

TAXATION

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

DEFERRED TAX

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

DEBTORS

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

CREDITORS

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1.

GM BIOPHARMA LTD (REGISTERED NUMBER: 11079986)

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 23 NOVEMBER 2017 TO 31 DECEMBER 2018**

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	£
VAT	70
Prepayments	<u>9,173</u>
	<u>9,243</u>

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	£
Trade creditors	(120)
Other creditors	10,000
Accruals and deferred income	<u>1,075</u>
	<u>10,955</u>

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	£
100	Ordinary	£1	<u>100</u>

7. RELATED PARTY DISCLOSURES

In other creditors there is a loan balance owing to Global Market Summits Limited, of which Mr A Uddin is a director of £10,000.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.